Imunon, INC. (IMNN) SEC Filings — 2026
2 SEC filings for Imunon, INC. (IMNN) in 2026.
Filings
- Imunon's Ovarian Cancer Drug Advances to Phase 3, Showing Strong Early Efficacy — 10-K · Mar 31, 2026
- Imunon, Inc. Files 8-K for Financial Results — 8-K · Mar 31, 2026